EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitFallberichtOpen Access · CC BY 4.0

Lenvatinib-Induced Acalculous Cholecystitis—An Often-Unrecognized Toxicity: A Case Series and Literature Review

Christos Cortas, Chloe Symeonidou, Haris Charalambous iD

Current Oncology · 14.03.2026 · 33 (3) · 167

DOI: 10.3390/curroncol33030167 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Oncology, online erschienen am 14.03.2026. Verfasst von Christos Cortas und 2 weiteren Autor:innen. Beteiligte Einrichtung: German Oncology Center, 4108 Limassol, Cyprus. Hauptthemen laut MEDLINE: Phenylurea Compounds, Quinolines, Acalculous Cholecystitis, Protein Kinase Inhibitors. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lenvatinib is an oral multi-kinase inhibitor which is used for the treatment of renal cell carcinoma, non-iodine avid differentiated thyroid cancer, hepatocellular carcinoma, and endometrial cancer. We present a series of three (3) patients who, whilst on treatment with Lenvatinib, developed symptoms and radiological findings of acalculous cholecystitis. A radiological review of another nineteen (19) Lenvatinib-treated patients in our center was undertaken, with another three (3) patients exhibiting radiological features of acalculous cholecystitis with gallbladder wall thickening and pericholecystic fluid collection but without abdominal pain or clinical symptoms of cholecystitis. A literature review is also presented of all previous publications of Lenvatinib-induced acalculous cholecystitis, including the results of two pharmacovigilance studies. This review provides evidence that Lenvatinib-induced acalculous cholecystitis is not as rare as initially thought from the Lenvatinib licensing studies; hence, this is an adverse event that merits more attention. Oncologists using Lenvatinib should be aware of this potential toxicity and be familiar with its management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phenylurea CompoundsQuinolinesAcalculous CholecystitisProtein Kinase InhibitorsAntineoplastic AgentsHumansFemaleMaleMiddle AgedAged

Stichwörter der Autor:innen

LenvatinibTKIadverse effectscholecystitissupportive care

Substanzen

Phenylurea CompoundsQuinolineslenvatinibProtein Kinase InhibitorsAntineoplastic Agents

Autor:innen und Institutionen

  • German Oncology Center, 4108 Limassol, Cyprus.
  • Bank of Cyprus Oncology Center, 2006 Nicosia, Cyprus.

ORCID-Profile: Haris Charalambous

Zitieren

APA

Cortas, C., Symeonidou, C., & Charalambous, H. (2026). Lenvatinib-Induced Acalculous Cholecystitis—An Often-Unrecognized Toxicity: A Case Series and Literature Review. Current Oncology, 33(3), 167. https://doi.org/10.3390/curroncol33030167

Vancouver

Cortas C, Symeonidou C, Charalambous H. Lenvatinib-Induced Acalculous Cholecystitis—An Often-Unrecognized Toxicity: A Case Series and Literature Review. Current Oncology. 2026;33(3):167. doi:10.3390/curroncol33030167

BibTeX
@article{Cortas2026,
  author = {Cortas, Christos and Symeonidou, Chloe and Charalambous, Haris},
  title = {Lenvatinib-Induced Acalculous Cholecystitis—An Often-Unrecognized Toxicity: A Case Series and Literature Review},
  journal = {Current Oncology},
  year = {2026},
  volume = {33},
  number = {3},
  pages = {167},
  doi = {10.3390/curroncol33030167}
}
Kostenlos starten →